Coave Therapeutics, Ocugen, Inc., and Nanoscope Therapeutics Inc. are set to present at the Retinal Cell and Gene Therapy Innovation Summit.

Ocugen, Inc.'s Dr. Benjamin Bakall will share data from OCU400 Phase 1/2 clinical trial, emphasizing the therapy's broad potential for multiple retinal diseases.

OCU400, a gene-agnostic modifier gene therapy, shows promise in treating retinitis pigmentosa and possibly other retinal diseases with one product.

Ocugen aims for Phase 3 liMeliGhT clinical trial approval by 2026, indicating a significant timeline for potential market entry.